Matthew Schiewer

About Matthew Schiewer
  • Deficiencies in the repair of DNA are a hallmark of cancer. A molecule, named PARP, is involved in DNA damage repair. The inhibition of PARP with specific medications is a potential therapy for advanced, metastatic prostate cancer.
  • Inhibition of PARP may also reduce cancer progression by reducing the activity of the androgen receptor which is the engine of prostate cancer.
  • In these investigations, Dr. Schiewer will study the role of PARP in the modulation of AR activity.

What this means to patients: Understanding the relationship between PARP inhibition and AR activity may provide new therapeutic opportunities for prostate cancer patients with advanced, metastatic disease.

Award

2013 Ben Franklin-PCF Young Investigator

Matthew Schiewer, PhD

Thomas Jefferson University

Mentors:

Karen Knudsen, PhD

Project Title:

Determining the translation capacity of the PARP-1/AR axis in prostate cancer